Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atovaquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atovaquone SCHEMBL21694 | 0.90 | MAPT (0.82) | MAPTHPGDMEN1KMT2ATP53 | |
| Atovaquone SCHEMBL20769805 | 0.90 | MAPT (0.82) | MAPTHPGDMEN1KMT2ATP53 | |
| Atovaquone SCHEMBL29559044 | 0.90 | MAPT (0.82) | MAPTHPGDMEN1KMT2ATP53 | |
| Atovaquone SCHEMBL9975142 | 0.90 | MAPT (0.82) | MAPTHPGDMEN1KMT2ATP53 | |
| Atovaquone SCHEMBL637069 | 0.90 | MAPT (0.82) | MAPTHPGDMEN1KMT2ATP53 | |
| Atovaquone SCHEMBL8848607 | 0.90 | MAPT (0.82) | MAPTHPGDMEN1KMT2ATP53 | |
| Atovaquone SCHEMBL1542719 | 0.90 | MAPT (0.82) | MAPTHPGDMEN1KMT2ATP53 | |
| Lawsone SCHEMBL8445723 | 0.85 | MAPT (0.55) | MAPTHPGDMEN1KMT2ATP53 | |
| SCHEMBL21695 | 0.81 | MAPT (1.00) | MAPTHPGDMEN1KMT2ATP53 | |
| SCHEMBL1649508 | 0.81 | MAPT (1.00) | MAPTHPGDMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594283-B2 | Mitochondria-targeted atovagone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4048246-B1 | MITOCHONDRIA-TARGETED ATOVAQUONE: A MORE POTENT AND MORE EFFECTIVE ANTITUMOR, ANTIMICROBIAL, AND ANTIMALARIAL DRUG | MEDICAL COLLEGE WISCONSIN INC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11964944-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | THE UNIVERSITY OF CHICAGO (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230140413-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | THE UNIVERSITY OF CHICAGO | 2023-05-04 | — | — | US | disclosed |
| US-20230017373-A1 | Mitochondria-Targeted Atovaqone: A More Potent and More Effective Antitumor, Antimicrobial, and Antimalarial Drug | THE MEDICAL COLLEGE OF WISCONSIN, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-4048246-A1 | MITOCHONDRIA-TARGETED ATOVAQUONE: A MORE POTENT AND MORE EFFECTIVE ANTITUMOR, ANTIMICROBIAL, AND ANTIMALARIAL DRUG | The Medical College of Wisconsin, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| US-11414385-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | THE UNIVERSITY OF CHICAGO | 2022-08-16 | — | — | US | disclosed |
| WO-2021081500-A1 | MITOCHONDRIA-TARGETED ATOVAQUONE: A MORE POTENT AND MORE EFFECTIVE ANTITUMOR, ANTIMICROBIAL, AND ANTIMALARIAL DRUG | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20200283391-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | THE UNIVERSITY OF CHICAGO | 2020-09-10 | — | — | US | disclosed |
| EP-3394032-A1 | COMPOUNDS AND METHODS FOR TREATING, DETECTING, AND IDENTIFYING COMPOUNDS TO TREAT APICOMPLEXAN PARASITIC DISEASES | The University of Chicago (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112678-A1 | COMPOUNDS AND METHODS FOR TREATING, DETECTING, AND IDENTIFYING COMPOUNDS TO TREAT APICOMPLEXAN PARASITIC DISEASES | MCLEOD RIMA (US) | 2017-06-29 | — | — | WO | disclosed |
| US-5670496-A | Treatment for toxoplasmosis with a composition comprising a folate antagonist and a spiropiperidyl derivative of rifamycin S | PALO ALTO MEDICAL FOUNDATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5665707-A | Treatment for toxoplasmosis with a composition comprising a lincosamide and a spiropiperidyl derivative of rifamycik S | PALO ALTO MEDICAL FOUNDATION (US) | 1997-09-09 | — | — | US | disclosed |
| US-5650405-A | Treatment for toxoplasmosis with a composition comprising a sulfonamide and a spiropiperidyl derivative of rifamycin S. | PALO ALTO MEDICAL FOUNDATION (US) | 1997-07-22 | — | — | US | disclosed |
| US-5648345-A | Treatment for toxoplasmosis with a composition comprising a macrolide antibiotic and a spiropiperidyl derivative of rifamycin S | PALO ALTO MEDICAL FOUNDATION (US) | 1997-07-15 | — | — | US | disclosed |
| US-5641769-A | treatment for toxoplasmoisis with a composition containing a hydroxynaphthoquinone and a spiropiperidyl derivative of rifamycin S. | PALO ALTO MEDICAL FOUNDATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0648121-B1 | USE OF RIFAMYCIN DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TOXOPLASMOSIS | PALO ALTO MEDICAL FOUND (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5529994-A | Treatment for toxoplasmosis | PALO ALTO MEDICAL FOUNDATION (US) | 1996-06-25 | — | — | US | disclosed |
| EP-0648121-A1 | USE OF RIFAMYCIN DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TOXOPLASMOSIS. | PALO ALTO MEDICAL FOUND (US) | 1995-04-19 | — | — | EP | disclosed |
| WO-1994025038-A1 | USE OF RIFAMYCIN DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TOXOPLASMOSIS | PALO ALTO MEDICAL FOUNDATION (US) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283391-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | TUBB1, MYADM, TUBB | MAPT 2969/4885HPGD 433/4885MEN1 4473/4885 |
| US-11964944-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | TUBB1, MYADM, TUBB | MAPT 2933/4885HPGD 354/4885MEN1 4456/4885 |
| US-20230140413-A1 | Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases | TUBB1, MYADM, TUBB | MAPT 2933/4885HPGD 354/4885MEN1 4456/4885 |
| US-11414385-B2 | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases | TUBB1, MYADM, TUBB | MAPT 2969/4885HPGD 433/4885MEN1 4473/4885 |
| US-20230017373-A1 | Mitochondria-Targeted Atovaqone: A More Potent and More Effective Antitumor, Antimicrobial, and Antimalarial Drug | MAVS, MT-ATP6, MT-ND2 | MAPT 2733/4885HPGD 718/4885MEN1 1436/4885 |
| US-12594283-B2 | Mitochondria-targeted atovagone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug | TFAM, MT-CO2, HADHA | MAPT 3721/4885HPGD 1000/4885MEN1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.